Recurrent Melanoma Active Not Recruiting Phase 1 Trials for Tremelimumab (DB11771)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01103635Tremelimumab and CP-870,893 in Patients With Metastatic MelanomaTreatment